Stay updated with breaking news from Pharma Sector. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite an over 86 percent gain in the stock in 2023 YTD, domestic brokerage house Investec sees pharma firm Orchid Pharma (ORCD) rising another 23 percent in the next 12 months. The brokerage has initiated coverage on the stock with a ‘buy’ call and a target price of ₹800.
The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) has on Monday lamented the government’s apathy towards...
B&K Securities airs concerns considering Cipla’s significant exposure to the US market, constituting 28% of consolidated sales
Investment banking firm expects pharma major’s revenue to reach Rs 10,164.6 crore by FY26
LAHORE: The Pakistan pharmaceutical industry has the potential to fetch precious foreign exchange through exports of...